ライフサイエンスコーパス: obese

1 into two BMI sub-categories (normal and high/obese).

2 normal weight vs. 27% positive in overweight/obese).

3 including patients that are hospitalized or obese.

4 his population, particularly in the morbidly obese.

5 s underweight, normal weight, overweight, or obese.

6 y; 45% of women were primipara and 24% were obese.

7 nt 2 years previously, 13 obese and nine non-obese.

8 nearly 3 in 4 US adults being overweight or obese.

9 ypoalbuminaemia and 80 patients (32.1%) were obese.

10 high-risk for cardiovascular disease are not obese.

11 stronger in children who were overweight and obese.

12 rease in left ventricular ejection fraction, obese +16+/-7% versus control +21+/-4%, P=0.031).

13 difference in overall resting ATP delivery (obese 2.5+/-0.9 umol.g(-1).s(-1) versus control 2.2+/-1.

14 ed in analysis of health outcomes, 7.3% were obese, 8.7% had depression, 19.5% reported smoking, 16.1

15 e classically activated M1-like phenotype in obese adipose tissue (AT) and may contribute to AT infla

16 t overexpression of MMP14 in the established obese adipose tissue leads to enlarged adipocytes and in

17 when overexpressing MMP14 in the early-stage obese adipose tissue, the transgenic mice showed a healt

18 collagenase, is dramatically upregulated in obese adipose tissue.

19 as a greater prevalence of keratoconus among obese adolescents (270/100,000) than of overweight (179/

20 n Conclusion, ANGPTL5 levels are elevated in obese adolescents and are associated with cardiovascular

21 Overweight and obese adolescents have higher odds of having keratoconus

22 red with the normal weight group, the OR for obese adolescents was 1.50 (95% confidence interval [CI]

23 Obese adults at risk for NASH were enrolled between 2015

24 iability in weight-loss using two cohorts of obese adults enrolled in the Diet Intervention Examining

25 ded as a non-pharmacological therapy in both obese and cancer situations.

26 Mice fed a high-fat diet (HFD) become obese and develop osteoarthritis (OA)-like lesions, incl

27 with higher blood concentrations reported in obese and diabetic individuals.

28 cteria and/or their products in the lungs of obese and diabetic patients promotes interactions betwee

29 sponse to regadenoson was less pronounced in obese and diabetic patients.

30 In obese and diabetic states, macrophage expression of puri

31 ic factor (BDNF) mutants, which are severely obese and have diminished glucose balance control.

32 h diabetes, and these patients are generally obese and hyperlipidemic.

33 ing insulin sensitivity in both diet-induced obese and lean mice.

34 HF-fed mice were equally obese and maintained lean mass regardless of genotype.

35 /late endpoint failures as less likely to be obese and more likely to be infected with Chlamydophila

36 s 2, and 7 were less likely to be overweight/obese and more likely to be underweight (referent: provi

37 besity as 49% of them were overweight and/or obese and nearly 39% at the lowest wealth quintile were

38 periodontal treatment 2 years previously, 13 obese and nine non-obese.

39 e the factors related to TGF-beta1 levels in obese and non-obese OSA patients.

40 n was 47%, with no significant difference in obese and non-obese subgroups (42.5% vs 49.6% respective

41 Obese and normal weight patients did not differ in relat

42 ate the recurrence of periodontal disease in obese and normal weight patients submitted to scaling an

43 cy and 3-6 months post-partum in a cohort of obese and normal-weight pregnant women, as well as in wo

44 T2D rats were obese and severely hyperlipidemic, with impaired glucose

45 ant immune cell type causing inflammation in obese and T2DM islets is the macrophage.

46 common: 40.2% of women and 19.4% of men were obese, and 53.1% of women and 41.0% of men were hypergly

47 palmitate was 11%, 19%, and 38% in the lean, obese, and obese-NAFLD groups, respectively.

48 are also activated in pancreatic islets from obese animals and humans with obesity and/or T2DM.

49 l TRPV4 channel activity and vasodilation in obese animals.

50 However, the majority of the obese are hyperleptinemic and do not respond to leptin t

51 but it was associated with the risk of being obese as an adult in comparison with not playing footbal

52 e found enrichment of Rho-GTPase pathways in obese asthmatic Th cells, identifying them as a novel th

53 nate the consequences of ATM accumulation in obese AT, lending further insight into obesity-related c

54 minant in lean AT and M1-like macrophages in obese AT.

55 Obese, black South African women (n = 45) were randomize

56 Obese BMI status appears to increase susceptibility to c

57 This study was conducted in 33 obese (BMI > 38.3) healthy male subjects aged 25 to 50 y

58 e born in Sub-Saharan Africa, and 12.6% were obese (BMI > = 30 kg/m(2)).

59 s within underweight (BMI < 18.5 kg/m(2)) or obese (BMI >= 30 kg/m(2)) categories, while the highest

60 metrix gene arrays and PCR in the skin of 10 obese (BMI 35-50) and 10 normal weight (BMI 18.5-26.9) p

61 x < 25) than in those who were overweight or obese (body mass index >= 25), at 99.2% versus 94.6%, re

62 ontrols [body mass index 24+/-3 kg/m(2)], 45 obese [body mass index 35+/-5 kg/m(2)]) without coexisti

63 vated ALT were younger and more likely to be obese (both P < 0.01).

64 Changes within the obese breast microenvironment may increase breast cancer

65 in achieved long-term outcomes exists among obese but otherwise healthy adults.

66 served according to fibrosis severity in non-obese, but not obese, subjects.

67 Obese children are vulnerable to vitamin D deficiency an

68 on of vitamin D deficiency in overweight and obese children by vitamin D3 supplementation with 1000 o

69 Obese children exhibited signs of increased collagen tur

70 study, we genetically screened 225 severely obese children from consanguineous Pakistani families th

71 sociated with pulmonary function deficits in obese children with asthma.Conclusions: We found enrichm

72 rmine, in vitamin D-deficient overweight and obese children, whether supplementation with vitamin D3

73 Bariatric surgery in obese cirrhotic patients is not associated with excessiv

74 ith a matched nonsurgical reference group of obese citizens.

75 inflammatory bowel disease (IBD) cohort, an obese cohort and two population-based cohorts.

76 e shown a relative AT failure in a monogenic obese cohort, a finding supported by observations in a n

77 ANGPTL5 levels were significantly higher in obese, compared with overweight and normal-weight adoles

78 ed 13-16 y) who ranged from normal weight to obese completed an fMRI paradigm where they viewed unhea

79 i-inflammatory lignan, on prostate cancer in obese conditions both in vitro and in vivo.

80 n blood pressure regulation under normal and obese conditions.

81 n; P<0.01) and was significantly higher than obese controls (women, 6.65+/-1.89 versus 5.66+/-1.37; m

82 ss-sectional comparison to normal-weight and obese controls without T2D) in individuals followed from

83 body BFKB8488A induced marked weight loss in obese cynomolgus monkeys while elevating serum adiponect

84 cess taste testing, with female offspring of obese dams showing an enhanced response to sucrose, and

85 versed leptin resistance in the offspring of obese dams.

86 zation prevents type 1 diabetes (T1D) in non-obese diabetic (NOD) mice but proved less effective in h

87 Localized delivery of proinsulin in non-obese diabetic (NOD) mice using the coated MN system sti

88 oreactive T cells in newly hyperglycemic non-obese diabetic (NOD) mice, protecting the insulin-produc

89 lacking functional leptin receptors, or from obese diabetic human donors failed to respond to leptin

90 Of note, non-obese diabetic mice with high blood glucose levels displ

91 er dose and less frequent injections, in non-obese diabetic mice with insulin resistance symptoms.

92 ncy and CDK4 inhibition, suggesting that the obese/diabetic environment confers cancer-selective depe

93 the most significantly upregulated genes in obese/diabetic liver tumors.

94 iver-specific cyclin D1 deficiency protected obese/diabetic mice against hepatic tumorigenesis, where

95 body (muGIPR-Ab) that protected diet-induced obese (DIO) mice against body weight gain and improved m

96 ion and decrease body weight in diet-induced obese (DIO) mice.

97 Severely obese donors more likely had diabetes mellitus (10.4% ve

98 ty have been identified in <=10% of severely obese European patients.

99 we investigated postmenopausal overweight or obese female subjects who either underwent CR for 3 mo f

100 es mellitus [T2DM]), divided in nonobese and obese groups, received a euglycemic insulin-clamp (40 mU

101 Compared to the mildly obese, the morbidly obese had higher levels of SPMs-RvD3, RvD4 and PD1-and w

102 heart increases ATP delivery through CK, the obese heart does not; this is associated with reduced sy

103 Next, obese HFD-fed mice were treated 12 weeks with (a) HFD +

104 The obese high CRP phenotype resembled the noninflammatory p

105 ing numbers of persons who are overweight or obese, higher rates of cardiomyopathy can be expected in

106 differentiation 4-positive) Th cells from 59 obese Hispanic and African American children with asthma

107 Myogenic tone was increased in obese human arteries with FTO inhibitors or prostaglandi

108 anges were similar to trends observed in the obese human gut microbiome, where overfeeding of the mic

109 Over 70% of obese humans have NAFLD and ketogenic diets are common w

110 ve demonstrated an obesity paradox such that obese ICU patients have lower mortality and better outco

111 d 12% to 18% lower plasma ALT among the most obese, in heavy drinkers, and in individuals carrying th

112 Treatment of obese inbred mice with RvE1, the downstream immunoresolv

113 er by 5% (95% CI: 4, 6), compared with never obese, increasing to 20% (95% CI: 17, 23) higher in thos

114 g/kg liposomal amphotericin B in 16 morbidly obese individuals (104-177 kg).

115 SMPD3 was elevated in PBMCs from obese individuals and positively corelated with TNF-alph

116 art disease, CVD, and all-cause mortality in obese individuals appeared largely limited to men, and t

117 e profile in a sample of healthy, mostly non-obese individuals from the general population and only f

118 erentiated, postmitotic myofiber nuclei from obese individuals had elevated gammaH2AX abundance compa

119 in NASH patients but not in fatty livers in obese individuals or in high-fat diet (HFD)-fed mice.

120 nce to COVID-19 prevention strategies in all obese individuals regardless of age.

121 Sites with periodontitis in obese individuals showed higher levels of IL-6 and TNF-a

122 a diverse repertoire in SAT of overweight or obese individuals.

123 ributing to the promotion of colon cancer in obese individuals.

124 l muscle insulin signalling in sedentary and obese individuals.

125 oL and URTI incidence outcomes in overweight/obese individuals.

126 ssociated with obesity but also found in non-obese individuals.

127 cose production was similar between lean and obese individuals.

128 sociated with prevalent and incident DSPN in obese individuals.

129 among subpopulations of current smokers and obese individuals.

130 for predicting weight loss in overweight and obese individuals.

131 tended to determine whether the treatment of obese, insulin-resistant humans with the beta3-AR agonis

132 f dietary NR supplementation in middle-aged, obese, insulin-resistant men affects mitochondrial respi

133 infusion into control diet-fed mice to mimic obese levels impaired NO production, vascular relaxation

134 rescued the impaired glucose homeostasis of obese male Dusp8-KO mice, respectively.

135 redictors of cardio-metabolic risk in 53 non-obese male individuals.

136 vity and enhanced TGFbeta1 within the ECM of obese mammary tissue may enhance breast cancer risk.

137 In the obese, many gene expression pathways were broadly downre

138 e often women (59%), African American (68%), obese (median body mass index 41), and hypertensive (98%

139 1000 mg/d for 6 wk in healthy overweight or obese men and women increased skeletal muscle NAD+ metab

140 dy was conducted in 13 healthy overweight or obese men and women.

141 Overweight and obese men did not have a lower mortality risk, irrespect

142 dle cerebral artery occlusion (tMCAO) in T2D/obese mice (after 7 months of high-fat diet [HFD]) and a

143 RSA (8-log(10) reduction) in infected PUs of obese mice after just four days of treatment.

144 and PKC (protein kinase C) were measured in obese mice and compared with lean controls.

145 rrelated with fasting plasma glucose in both obese mice and humans.

146 and reversed atrial fibrosis in diet-induced obese mice as compared with controls.

147 were significantly increased in diet-induced obese mice as compared with controls.

148 and females, although they are increased in obese mice compared with lean mice of both sexes.

149 Unexpectedly, depletion of macrophages in obese mice enhanced mammary epithelial cell stem/progeni

150 Here, we demonstrate that ATM from obese mice exhibit metabolic profiles characterized by e

151 e 1 enzymes at myoendothelial projections in obese mice generated higher levels of nitric oxide and s

152 ng metabolic reprogramming by tumor cells in obese mice improves anti-tumor immunity.

153 Administration of FGF21 in obese mice improves defective autophagy and hepatosteato

154 In obese mice on a high-fat diet, the effects of metformin

155 Islets from prediabetic obese mice show significantly higher CypD-dependent prot

156 Pacing-induced AF in 100% of diet-induced obese mice versus 25% in controls (P<0.01) with increase

157 latable food consumption in the offspring of obese mice was a change in taste function.

158 n resistance in liver and skeletal muscle of obese mice, and such effects were associated with activa

159 metabolism and insulin sensitivity in female obese mice, but did not affect CL-induced body weight lo

160 Previous studies show that in obese mice, hyperinsulinemia plays a crucial role in bet

161 Diet-induced obese mice, including wild-type or whole body knockout (

162 lic fatty liver disease (NAFLD) patients and obese mice, occupancy of SHP and DNMT3A and DNA methylat

163 ce, as well as leptin-resistant diet-induced obese mice, show significant reductions of sympathetic i

164 lly identical 10-week-old female New Zealand Obese mice, which differ in their degree of hyperglycemi

165 of NRG4 reduced weight gain in diet-induced obese mice, while overexpression of ANGPTL8 resulted in

166 microenvironment and anti-tumor immunity in obese mice.

167 olic dysfunction in genetic and diet-induced obese mice.

168 L-induced body weight loss in male or female obese mice.

169 wn-regulated in serum exosomes and islets of obese mice.

170 detected in plasma from moderately inflamed obese mice.

171 CK are produced in the endocrine pancreas of obese mice.

172 insulin resistance in high-fat-diet-induced obese mice.

173 in the same individuals and are increased in obese mice.

174 otects against cardiomyopathy in chronically obese mice.

175 ms associated with nonatopic inflammation in obese minority children with asthma.Methods: CD4(+) (clu

176 onors with high macrosteatosis grafts in the obese modern liver transplant recipient population.

177 sucrose, sucralose and high fat diet if from obese mothers.

178 TG concentrations has been observed in some obese mothers.

179 ated in the hypothalamus of neonates born to obese mothers.

180 as down-regulated in the visceral fat of two obese mouse models and obese patients.

181 normal-weight (n = 31), overweight (n = 29), obese (n = 30)] performed a sequential decision-making t

182 Six subjects in the obese-NAFLD group were also evaluated before and after a

183 as 11%, 19%, and 38% in the lean, obese, and obese-NAFLD groups, respectively.

184 ased from the lean-NL to the obese-NL to the obese-NAFLD groups.

185 ased from the lean-NL to the obese-NL to the obese-NAFLD groups.

186 emia after glucose ingestion in obese-NL and obese-NAFLD is due to an increase in insulin secretion,

187 fatty liver disease (NAFLD) and prediabetes (obese-NAFLD; n = 22).RESULTSInsulin sensitivity progress

188 NHyperinsulinemia after glucose ingestion in obese-NL and obese-NAFLD is due to an increase in insuli

189 gressively increased from the lean-NL to the obese-NL to the obese-NAFLD groups.

190 gressively increased from the lean-NL to the obese-NL to the obese-NAFLD groups.

191 ects with normal IHTG and glucose tolerance (obese-NL; n = 24), and (c) obese subjects with nonalcoho

192 gnition, but VAT transplants from comparably obese NLRP3-KO donors (TRANSKO) had no effect.

193 PM and platelet levels decreased in morbidly obese nondiabetic subjects but not in diabetic subjects,

194 analysed fasting (8 h) blood samples from an obese, normoglycemic cohort and an obese, T2DM cohort of

195 ormal weight (NW, BMI = 18.5-24.9 kg/m2) and obese (OB, BMI >30 kg/m2) mothers.

196 trast to their lean littermates, genetically obese (ob/ob) mice have a defective inner colonic mucus

197 ght (odds ratio, 1.13 [95% CI, 1.1-1.2]) and obese (odds ratio, 1.5 [95% CI, 1.4-1.6]).

198 al (May 2017 through July 2018), abdominally obese or dyslipidemic participants in Israel were random

199 evels during the OGTT were lower than in the obese or normal-weight pregnant women (basal levels: 13.

200 s had higher odds of being overweight and/or obese (OR: 1.89, 95% CI: 1.62-2.20) and lower odds of be

201 related to TGF-beta1 levels in obese and non-obese OSA patients.

202 (NW: 18.5-24.9 kg/m2, n = 88) and overweight/obese (OW: 25-35 kg/m2, n = 86) women between 0.5 and 9

203 e from Sub-Saharan Africa (p = 0.023) and be obese (p = 0.048).

204 Conclusion Dyspnea improved in obese participants after weight reduction, which correla

205 ciations with incident DSPN were positive in obese participants but null or inverse for nonobese part

206 positively associated with prevalent DSPN in obese participants, whereas corresponding estimates for

207 act2 prevalence of 5.88% in statin-medicated obese participants.

208 tomic profiles of livers starting from a 910-obese-patient cohort, which was further stratified based

209 Overweight/obese patients (BMI > 25) did not show a significant dif

210 A logistic regression model showed that non-obese patients (BMI < 30 kg/m(2)) were at significantly

211 AF type before and after BS in 220 morbidly obese patients (body mass index, >=40 kg/m(2)).

212 We assessed overall survival in obese patients (those with a body-mass index [BMI] >=30

213 r disease (NAFLD) is a frequent condition in obese patients and regularly progresses to non-alcoholic

214 lysed differences in gene expression between obese patients and those at a normal weight in the COMPA

215 umour and peritumoral adipose tissue between obese patients and those at a normal weight.

216 Obese patients are also at higher risk for venous thromb

217 uite effective, but is reserved for the most obese patients because of the associated intraoperative/

218 ptomic differences in the primary tumours of obese patients compared with those of a normal weight.

219 total undigested adipose tissue (ATs), from obese patients has decreased LAL expression compared wit

220 In addition, obese patients have a higher incidence of early de-novo

221 Compared with nonobese patients, obese patients have higher incidences of conduction diso

222 d peritumoral adipose tissue inflammation in obese patients relative to those at a normal weight, esp

223 ne expression analysis of liver samples from obese patients revealed a negative correlation between C

224 There is no difference in 2-year outcomes of obese patients seeking VHR who undergo prehabilitation v

225 erative prehabilitation improves outcomes of obese patients seeking VHR.

226 Tumours of obese patients showed higher angiogenic scores on gene-s

227 Prehabilitation may not be warranted in obese patients undergoing elective VHR.

228 Thirty-two obese patients underwent one of three treatments: (1) VS

229 erformed a prospective study of 180 severely obese patients with biopsy-proven NASH, defined by the N

230 geted therapies may improve therapeutics for obese patients with breast cancer and identify patient p

231 e conducted a case-controlled study with 106 obese patients with cirrhosis (cases) and 317 age, sex,

232 ribute to the apparent survival advantage in obese patients with clear cell RCC compared with patient

233 Importantly, obese patients with diabetes have a higher risk of infec

234 Furthermore, obese patients with ILD had an elevated risk of death (H

235 In severely obese patients with previous MI, metabolic surgery is as

236 We hypothesize that prehabilitation in obese patients with VHR results in more hernia- and comp

237 ody mass index-, and type of surgery-matched obese patients without cirrhosis (controls) who underwen

238 Obese patients(BMI 30-40) seeking VHR were randomized to

239 s SPECT in the overall population, in women, obese patients, and patients undergoing pharmacological

240 r for CAD detection and assessment of women, obese patients, and patients undergoing pharmacological

241 In obese patients, the overall incidence of CD (3.1% versus

242 gher vulnerability to atrial fibrillation of obese patients.

243 cessive mortality compared with noncirrhotic obese patients.

244 ation was also observed in the arteries from obese patients.

245 ws screening of NAFLD as well as fibrosis in obese patients.

246 e visceral fat of two obese mouse models and obese patients.

247 ta-catenin in physically fit, overweight and obese patients.

248 ntrol and ACC2 iKO mice exhibiting a similar obese phenotype, increasing FAO oxidation by deletion of

249 In comparison to normal-weight and obese pregnant women, women with a history of RYGB opera

250 gestational day 18.5 (E18.5) of HFD-induced obese rat dams.

251 Diet-induced obese rats, which remained relatively hyperleptinemic wh

252 whereas aspirin use and being overweight or obese (relative to normal BMI) were significantly associ

253 dren who were normal weight, overweight, and obese, respectively.

254 Prospective analysis of 5373 overweight/obese Spanish adults (aged 55-75 y) with metabolic syndr

255 hine learning (hierarchical clustering) with obese status and 13 inflammatory biomarkers as input var

256 equencing of liver biopsy specimens from the obese steatotic individuals revealed perturbations in th

257 We subjected 15 healthy lean and 15 obese steatotic male participants to a pancreatic clamp

258 each 10-parts per billion increase in NO(2), obese students had a significant increase in the odds of

259 h no significant difference in obese and non-obese subgroups (42.5% vs 49.6% respectively; p=non-sign

260 ith intellectual disability in 22 additional obese subjects (10%).

261 aphy-tandem mass spectrometry in 29 morbidly obese subjects (13 with diabetes) and 15 nondiabetic, mi

262 1 (95% CI, 2.81-7.89) was found for severely obese subjects (BMI >=35 kg/m(2)), as compared with BMI

263 Obese subjects (body mass index 35 to 55 kg/m(2)) were r

264 In overweight or obese subjects at high cardiovascular risk, levels of tr

265 In conclusion, the development of IR in obese subjects is associated with a decline in MCR(I) th

266 lammation originating from adipose tissue in obese subjects is widely recognized to induce insulin re

267 um or adipose tissue RBP4 levels in morbidly obese subjects may cause hepatic and systemic insulin re

268 In overweight and obese subjects undergoing a Mediterranean-type low-calor

269 nd visceral adipose tissue (VAT) in morbidly obese subjects undergoing Roux-en-Y gastric bypass surge

270 lucose tolerance (obese-NL; n = 24), and (c) obese subjects with nonalcoholic fatty liver disease (NA

271 and glucose tolerance (lean-NL; n = 14), (b) obese subjects with normal IHTG and glucose tolerance (o

272 d propionate are elevated, especially in non-obese subjects with significant fibrosis.

273 s given usual care in the SOS study (Swedish Obese Subjects).

274 ee fatty acids at concentrations observed in obese subjects.

275 13 with diabetes) and 15 nondiabetic, mildly obese subjects.

276 greater melanoma aggressiveness only in non-obese subjects.

277 ota associated with fibrosis severity in non-obese subjects.

278 g to fibrosis severity in non-obese, but not obese, subjects.

279 s from an obese, normoglycemic cohort and an obese, T2DM cohort of UAE nationals, employing clinical

280 stronger among those who were overweight and obese than among those of normal weight (P for interacti

281 Compared to the mildly obese, the morbidly obese had higher levels of SPMs-RvD3

282 present 4 cases of anticoagulant use in the obese to illustrate the common challenges faced by clini

283 issue macrophages isolated from diet-induced obese Ucp2(DeltaLysM) mice showed decreased TNFalpha sec

284 highest in those with T2D (15.8% versus 5.7% obese versus 0% normal weight).

285 , 1.27 to 2.09; P < .001), respectively, for obese versus lean groups.

286 R(I) during the insulin clamp was reduced in obese versus nonobese NGT (0.60 +/- 0.03 vs. 0.73 +/- 0.

287 Increased activation of HIF-1alpha in ATM of obese visceral adipose tissue resulted in induction of I

288 intervention was conducted in 305 overweight/obese volunteers involving 2 energy-restricted diets (30

289 etabolic health parameters in overweight and obese volunteers.

290 lm-Bonferroni correction for 16 comparisons (obese vs normal weight and overweight vs normal weight f

291 men gaining weight below quartile 1 (14.8%), obese women gaining weight above quartile 3 (14.3%), wom

292 Among obese women undergoing cesarean delivery, prophylactic n

293 By multivariate analysis, obese women with WL < 5% had a lower 60-mo mortality ris

294 iated with reduced odds of current asthma in obese women, and an elevated serum estradiol was associa

295 al-site infection after cesarean delivery in obese women.

296 reduced risk of breast cancer among severely obese women.

297 of unknown cause, usually observed in young, obese women.

298 t in NLRP3-KO mice, we transplanted VAT from obese WT or NLRP3-KO donors into lean recipient mice.

299 acranial pressure that predominantly affects obese young women.

300 adults without recent dentist visits and in obese youth.